secwatch / observer
8-K filed May 27, 2026, 4:30 PM ET ticker ALNY CIK 0001178670
leadership confidence high sentiment neutral materiality 0.50

Alnylam elects Benjamin F. Cravatt to board; shareholders re-elect directors and approve say-on-pay

ALNYLAM PHARMACEUTICALS, INC.

item 5.02item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001628280-26-038499
form_type
8-K
ticker
ALNY
cik
0001178670
company_name
ALNYLAM PHARMACEUTICALS, INC.
filed_at
2026-05-27T20:30:22+00:00
discovered_at
2026-05-27T20:32:00.370237+00:00
generated_at
2026-05-27T20:38:07.487433+00:00
sec_items
["5.02", "5.07", "9.01"]
event_type
leadership
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001628280-26-038499
json_url
https://secwatch.observer/filing/0001628280-26-038499.json
markdown_url
https://secwatch.observer/filing/0001628280-26-038499.md
text_url
https://secwatch.observer/filing/0001628280-26-038499.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Benjamin F. Cravatt

Director
ALNY · ALNYLAM PHARMACEUTICALS, INC.
Effective
2026-06-01
Filed
May 27, 2026, 4:30 PM ET
Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Source-grounded claims

a7015ccdb8

Benjamin F. Cravatt was elected as Director at ALNYLAM PHARMACEUTICALS, INC..

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

MGNO

Magnolia Bancorp names Robert Kimbro President/CEO; Hurley becomes Executive Chair

Magnolia Bancorp, Inc. June 1, 2026, 2:15 PM ET leadership Items 5.02, 5.07, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

On May 28, 2026, both the Company and the Association appointed Robert W. Kimbro as their President and Chief Executive Officer effective as of June 1, 2026.

Filing page SEC filing

FIBK

First Interstate BancSystem: three directors retire per age policy; charter amended to plurality voting

FIRST INTERSTATE BANCSYSTEM INC May 29, 2026, 4:26 PM ET leadership Items 5.02, 5.03, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

on May 27, 2026, each of Ms. Patricia L. Moss and Messrs. David L. Jahnke and Stephen M. Lacy, each having reached the retirement age of 72, was deemed to have retired and resigned automatically from the Company’s Board of Directors

Filing page SEC filing

BELFA

Bel Fuse names Kenneth Lai as SVP ITDS; annual meeting approves 2026 equity plan

BEL FUSE INC /NJ May 28, 2026, 2:24 PM ET leadership Items 5.02, 5.07, 9.01

same fact type: executive_change same SEC item: 5.02, 5.07, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

on May 22, 2026, the Company determined to name Kenneth Lai as Senior Vice President ITDS, effective late second quarter or early third quarter of 2026. In this role, Mr. Lai’s responsibilities expand to include the Company’s India and private label operations, in addition to China and other Asia locations. As a result of this change in responsibilities, Mr. Lai is no longer determined to be an “executive officer” or “officer” of the Company as defined in Rules 3b-7 and 16a-1(f) under the Securities Exchange Act of 1934, as amended, respectively.

Filing page SEC filing

LOGC

ContextLogic appoints Scott Stewart as CFO & COO effective June 1; interim CFO resigns

ContextLogic Holdings Inc. June 1, 2026, 4:15 PM ET leadership Items 5.02, 7.01, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

On June 1, 2026 the Company also announced the appointment of Scott Stewart, age 53, as Chief Financial Officer and Chief Operating Officer, effective June 1, 2026 (the “Effective Date”).

Filing page SEC filing

VMI

Former CFO Thomas Liguori enters separation agreement; $4.9M retirement benefits

VALMONT INDUSTRIES INC June 1, 2026, 4:15 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

Valmont Industries Inc. previously reported the appointment of John Schwietz as Valmont’s Executive Vice President and Chief Financial Officer and Corporate Secretary, effective April 8, 2026, to succeed Thomas Liguori.

Filing page SEC filing

GPOR

Gulfport Energy appoints Domenic Dell'Osso to Board; CEO role effective May 28, 2026

GULFPORT ENERGY CORP June 1, 2026, 4:10 PM ET leadership Items 5.02, 5.07

same fact type: executive_change same SEC item: 5.02, 5.07 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

On May 28, 2026, the Board voted to increase the size of the Board to seven members and appointed Domenic J. Dell’Osso, Jr. to serve as a member of the Board until the 2027 Annual Meeting of Stockholders or until his successor is duly elected and qualified.

Filing page SEC filing

PSQH

PSQ Holdings SVP of People Michael Hebert resigns; severance of $137,500

PSQ Holdings, Inc. June 1, 2026, 4:02 PM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

On May 26, 2026, Michael Hebert resigned from his position of Senior Vice President of People of PSQ Holdings, Inc. (the “Company”), effective May 31, 2026.

Filing page SEC filing

FSBW

FS Bancorp names Matt Mullet CEO as planned; Joe Adams retires but stays on board

FS Bancorp, Inc. June 1, 2026, 11:31 AM ET leadership Items 5.02, 9.01

same fact type: executive_change same SEC item: 5.02, 9.01 same event type: leadership similar materiality

This filing

Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.

Comparable filing

it has named Matthew D. Mullet as Chief Executive Officer of the Company effective June 1, 2026

Filing page SEC filing

Source: SEC EDGAR
accession 0001628280-26-038499
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.